Pfizer Relpax
Executive Summary
Eletriptan for treatment of migraine receives "approvable" letter Oct. 29
You may also be interested in...
Celexa May Be Hidden Trophy In Warner-Lambert Bidding War
Forest's antidepressant Celexa could either become the centerpiece of a newly created neuropharmaceutical marketing giant or an outlicensing candidate, depending on whether American Home Products or Pfizer prevails in its bid to acquire Warner-Lambert.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011